BlackRock, Inc. 13D and 13G filings for Poseida Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Poseida Therapeutics, Inc. PSTX | BlackRock Inc. BLK | 5,123,969 5.300% | 0 (Unchanged) | Filing |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Poseida Therapeutics, Inc. PSTX | BlackRock Inc. BLK | 5,123,969 5.300% | 296,730 (+6.15%) | Filing |
| 2024-06-07 1:30 pm Sale | 2024-05-31 | 13G | Poseida Therapeutics, Inc. PSTX | BlackRock Inc. BLK | 4,827,239 4.970% | -203,934 (-4.05%) | Filing |
| 2024-01-31 2:08 pm Purchase | 2023-12-31 | 13G | Poseida Therapeutics, Inc. PSTX | BlackRock Inc. BLK | 5,031,173 5.300% | 5,031,173 (New Position) | Filing |